Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Minority Interest (2016 - 2017)

Rein Therapeutics filings provide 2 years of Minority Interest readings, the most recent being $130.4 million for Q2 2017.

  • For the quarter ending Q2 2017, Minority Interest changed N/A year-over-year to $130.4 million, compared with a TTM value of $130.4 million through Jun 2017, changed N/A, and an annual FY2016 reading of $129.7 million, up 32.83% over the prior year.
  • Minority Interest hit $130.4 million in Q2 2017 for Rein Therapeutics, up from $129.7 million in the prior quarter.
  • The five-year high for Minority Interest was $130.4 million in Q2 2017, with the low at $129.7 million in Q4 2016.